Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,391 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Pill Clear all

Conditions: QTc Interval
Interventions: Droxidopa, Moxifloxacin, Placebo; Drug
Lead sponsor: Chelsea Therapeutics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Arnica, Third Molar Extraction
Interventions: SinEcch, Placebo; Drug · Other
Lead sponsor: Tufts University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Entinostat, Atezolizumab, Placebo; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Bakersfield, California • Fullerton, California + 15 more

Conditions: Parkinson's Disease
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Transgender Women
Interventions: Placebo, Progesterone; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV, Endothelial Dysfunction, Oxidative Stress
Interventions: PharmaNAC (N-acetylcysteine), Matching placebo; Dietary Supplement
Lead sponsor: Indiana University; Other
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Frailty, Inflammation
Interventions: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 65 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior, Challenging Behavior
Interventions: Propranolol; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 12 Years to 30 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Postmenopausal Symptoms
Interventions: Brisdelle (paroxetine mesylate), Placebo capsules; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 40 Years and older · Female only
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 74
States / cities: Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 63 more

Conditions: Alcohol Craving, Mood Changes
Interventions: Atomoxetine, Strattera; Drug
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 21 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer
Interventions: Lovaza, L-Arginine Powder, Vitamin C; Drug
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Fibromyalgia
Interventions: Ketotifen, Placebo (Sugar Pill); Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Medication Absorption
Interventions: Water, Parmalat™ Whole Milk, Similac Pro-Advance™, Ensure Plus™, Furosemide 20 MG; Dietary Supplement · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Contraception
Interventions: Misoprostol, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pregnancy
Interventions: Calcium or Placebo; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Oakland, California

Conditions: Anorexia Nervosa
Interventions: amisulpride, bromocriptine, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Diego, California

Conditions: Bipolar Disorder, Anxiety Disorder
Interventions: Risperidone; Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
Interventions: Varenicline, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 10
States / cities: Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more

Conditions: Parkinson's Disease
Interventions: Amantadine, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 30 Years to 90 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 2 more

Conditions: Chronic Low Back Pain
Interventions: Naproxen, Placebo, Omeprazole; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Binge Eating Disorder Associated With Obesity
Interventions: Zonegran, sugar pill; Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Type 1 Diabetes
Interventions: Sitagliptin, Sugar Pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sleep Disturbance
Interventions: Melatonin 3 mg, Melatonin 0.5 mg, Cellulose placebo pill; Dietary Supplement · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose

Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

The Effect of Donepezil on Gait and Balance in Parkinson's Disease

Progesterone in Gender Affirming Hormone Therapy Study

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

Reducing Frailty for Older Cancer Survivors Using Supplements

Propranolol for Challenging Behaviors in Autism

Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)

A Dose Response Effect of Atomoxetine to the Acute Effects of Alcohol

Immunonutrition for Diabetic Foot Ulcers

Novel Use of (Oral) Ketotifen for the Treatment of Fibromyalgia: A Pilot Study

Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide

Misoprostol Prior to Intrauterine Device (IUD) Insertion in Nulliparous Women

Bone Health in Pregnancy

Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa

Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

Validation of Dyskinesia Rating Scales

Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

Assessing Glucose Effects of Sitagliptin (Januvia) in Adult Patients With Type 1 Diabetes

Feasibility Study of Personalized Trials to Improve Sleep Quality